Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Seclidemstat e Azacitidina per il trattamento della sindrome mielodisplastica o della leucemia mielomonocitica cronica

17 settembre 2026 aggiornato da: M.D. Anderson Cancer Center

Studio di fase I/II su SP-2577 (Seclidemstat) in combinazione con azacitidina per pazienti con sindromi mielodisplastiche e leucemia mielomonocitica cronica

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine may help block the formation of growths that may become cancer. Giving seclidemstat and azacytidine may kill more cancer cells.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To determine the safety, tolerability and maximum tolerable dose (MTD) of seclidemstat in combination with azacitidine.

II. To assess overall response rate (ORR) to seclidemstat in combination with azacitidine.

SECONDARY OBJECTIVES:

I. To assess overall survival (OS), duration of response (DOR), relapse-free survival (RFS), and leukemia-free survival (LFS) and safety profile.

II. Correlative studies including correlation of response with disease subtypes, genomic profile and in vitro studies.

OUTLINE: This is a phase I, dose-escalation study of seclidemstat followed by a phase II dose-expansion study.

Patients receive azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on days 1-7. Patients also receive seclidemstat orally (PO) once daily (QD) on day 1 of cycle 1 and PO twice daily (BID) on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 possbile dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine until the phase 2 recommended dose or maximum tolerated dose is determined. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days, and then every 6 months thereafter

Tipo di studio

Interventistico

Iscrizione (Effettivo)

24

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • M D Anderson Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age >= 18 years as myelodysplastic syndrome (MDS) is a very rare disease in the pediatric setting

  • Diagnosis of MDS or chronic myelomonocytic leukemia (CMML) according to World Health Organization (WHO) and:

    • MDS with int-1, int-2, or high risk by International Prognostic Scoring System (IPSS), or CMML-1/CMML-2 , myeloproliferative CMML (white blood cell [WBC] >= 13 x 10^9/L) or CMML-0 with high-risk molecular features (known mutations in ASXL1, SETBP1, RUNX1, NRAS, TP53 or more than 3 mutations).
    • No response after 6 cycles of azacitidine, decitabine, guadecitabine, ASTX030 or ASTX727 or relapse or progression after any number of cycles
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 50 ml/min for patients with creatinine levels > 1.5 x ULN

  • Adequate hepatic function with total bilirubin < 2 x ULN (will allow less than 5 x ULN if Gilbert's syndrome at investigator's discretion)

  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x ULN

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Patient (or patient's legally authorized representative) must have signed an informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study

  • Prior hydroxyurea for control of leukocytosis or use of hematopoietic growth factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], Procrit, Aranesp, thrombopoietins) is allowed at any time prior to or during study if considered to be in the best interest of the patient

Exclusion Criteria:

  • Uncontrolled infection not adequately responding to appropriate antibiotics

  • New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50% by echocardiogram or multigated acquisition (MUGA) scan

  • History of myocardial infarction within the last 6 months or unstable/uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias

  • Baseline corrected QT interval by Fridericia formula (QTcF) (Fridericia) >= 450 msecs and long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome

  • Currently receiving any of the following substances and cannot be discontinued 14 days for CYP inhibitors prior to cycle 1 day 1:

    • Moderate or strong inhibitors or inducers of major CYP isoenzymes, including grapefruit, grapefruit hybrids, pomelos, star fruit and Seville oranges
    • Moderate or strong inhibitors or inducers of major drug transporters
    • Substrates of CYP3A4/5 with a narrow therapeutic index
  • Female patients who are pregnant or lactating

  • Patients with reproductive potential who are unwilling to following contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine devices [IUD], double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the study

  • Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta human chorionic gonadotropin [HCG]) pregnancy test at screening

  • Patients receiving any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy

  • Evidence of graft versus host disease or prior allogeneic (allo)-stem cell transplantation within 6 months of cycle 1 day 1 or receiving immunosuppressants following a stem-cell procedure

  • Patients known to be positive for hepatitis B surface antigen expression or with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Patients with history of human immunodeficiency virus (HIV) disease are also excluded from the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (azacitidine, seclidemstat)

Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7. Patients also receive seclidemstat PO QD on day 1 of cycle 1 and PO BID on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 planned dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Given IV or SC

Altri nomi:
  • 5AZC
  • 5-AC
  • 5-azacitidina
  • 5-AZC
  • Azacitidina
  • Azacitidina, 5-
  • Ladakamicina
  • Milosar
  • U-18496
  • Vidazza
  • Onureg

Given PO

Altri nomi:
  • SP-2577
  • Inibitore LSD1 SP-2577
  • SP 2577
  • SP2577

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response rate
Lasso di tempo: Up to the end of four cycles of treatment (1 cycle = 28 days)

Will be defined as complete response, partial response, marrow complete response, or hematological improvement. Will be estimated for all patients along with the 95% confidence interval.

Up to the end of four cycles of treatment (1 cycle = 28 days)
Incidence of adverse events
Lasso di tempo: Up to 1 year

The severity of the toxicities will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number and percent of subjects with treatment-emergent adverse events will be summarized according to intensity and drug relationship, and categorized by System Organ Class and preferred term by dose level/part. All reported adverse events that occur after signing informed consent will be included in the analysis of all reported adverse events. Exposure to study drug and reasons for discontinuation of study drug will be tabulated.

Up to 1 year

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall survival
Lasso di tempo: Time from treatment start till death or last follow-up, assessed up to 1 year

Will be listed and summarized by the Kaplan-Meier estimator, if needed.

Time from treatment start till death or last follow-up, assessed up to 1 year
Duration of response
Lasso di tempo: Time from the first documented onset of partial response or complete response to the date of progressive disease/relapse, assessed up to 1 year

Will be listed and summarized by the Kaplan-Meier estimator, if needed.

Time from the first documented onset of partial response or complete response to the date of progressive disease/relapse, assessed up to 1 year
Leukemia free survival
Lasso di tempo: Time from treatment start to transformation to acute myeloid leukemia or death, whichever comes first, assessed up to 1 year

Will be listed and summarized by the Kaplan-Meier estimator, if needed.

Time from treatment start to transformation to acute myeloid leukemia or death, whichever comes first, assessed up to 1 year
Relapse-free survival
Lasso di tempo: Time from start of response to the date of event defined as the first documented progressive disease/relapse or death, whichever comes first, assessed up to 1 year

Will be listed and summarized by the Kaplan-Meier estimator, if needed.

Time from start of response to the date of event defined as the first documented progressive disease/relapse or death, whichever comes first, assessed up to 1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Guillermo M Bravo, M.D. Anderson Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 luglio 2021

Completamento primario (Stimato)

11 settembre 2027

Completamento dello studio (Stimato)

11 settembre 2027

Date di iscrizione allo studio

Primo inviato

28 gennaio 2021

Primo inviato che soddisfa i criteri di controllo qualità

28 gennaio 2021

Primo Inserito (Effettivo)

2 febbraio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2020-0487
  • 2020-0487 (Altro identificatore: M D Anderson Cancer Center)
  • NCI-2020-14163 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .